Who
Norbert W. Bischofberger
Director
Company insider
Files Form 4 as: Director, Vir Biotechnology; President & CEO, Kronos Bio; Director, Morphic Holding; EVP, R&D and CSO, Gilead Sciences.
In numbers
- Trades disclosed
- 515
- Buys
- 13
- Sells
- 45
- Bought
- $9.6M
- Sold
- $289.3M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 25 Jan 2006
- Last trade
- 27 May 2026
- Last filed
- 28 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 May 2026filed 28 May 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —297,186 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —570,868 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —699,800 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Bio | SEC FORM 4 Code U | $6.2M10,802,138 at $0.57 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Bio | SEC FORM 4 Code U | $150K263,750 at $0.57 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Bio | SEC FORM 4 Code U | $150K263,750 at $0.57 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Bio | SEC FORM 4 Code U | $150K263,750 at $0.57 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Bio | SEC FORM 4 Code U | $150K263,750 at $0.57 | filing |
| 6 Jun 2025filed 6 Jun 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —10,667 at $0.00 | filing |
| 6 Jun 2025filed 6 Jun 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —10,667 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 16 Aug 2024filed 20 Aug 2024 | Morphic Holdingoption or derivative | SEC FORM 4 Code D | —24,000 | filing |
| 16 Aug 2024filed 20 Aug 2024 | Morphic Holdingoption or derivative | SEC FORM 4 Code D | —12,000 | filing |
| 16 Aug 2024filed 20 Aug 2024 | Morphic Holdingoption or derivative | SEC FORM 4 Code D | —9,888 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?GILD · insidermonkey.com · 22 Oct 2026Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?GILD · fool.com · 18 Oct 2026Gilead Sciences Clears Its February High at $153.54GILD · 247wallst.com · 15 Oct 2026
0 headlines in the last 90 days name Norbert W. Bischofberger; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.